Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dynavax Technologies (NQ: DVAX )

13.01 +0.99 (+8.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies

< Previous 1 2 3 4 5 6 Next >
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Dynavax Technologies's Return On Capital Employed Insights
Via Benzinga
JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know
Via Benzinga
Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript
DVAX earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Weyerhaeuser Co (NYSE: WY) a lot. 
Via Benzinga
Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript
DVAX earnings call for the period ending September 30, 2022. 
Via The Motley Fool
China-Based COVID-19 Shot Neutralizes Omicron Subvariants
Via Benzinga
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
From Clover Biopharmaceuticals
Via GlobeNewswire
The 7 Most Undervalued Long-Term Stocks to Buy in January
Investors should keep an eye on these severely undervalued long-term stocks as we get deeper into New Year 2023. 
Via InvestorPlace
Our 7 Top Small-Cap Stock Picks for 2023
Most of the names on this list of small-cap stock picks for 2023 are ready to rebound from a tough year in the markets. 
Via InvestorPlace
Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission
Via Benzinga
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
From Clover Biopharmaceuticals
Via GlobeNewswire
Earnings Preview For Dynavax Technologies
Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential
If under-the-radar small-cap stocks are your jam, I’ve got three selections from the S&P SmallCap 600 that might be right up your alley. 
Via InvestorPlace
Clover Provides Update on 2022 Corporate Milestones
From Clover Biopharmaceuticals
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2022
Upgrades 
Via Benzinga
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations
Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).  
Via Benzinga
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
Dynavax Technologies: Q2 Earnings Insights
Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.